Ibio Stock Price, News & Analysis

iBio (NASDAQ:IBIO) has announced a conference call scheduled for June 24, 2025, at 8:30 a.m. ET to discuss its obesity and cardiometabolic disease pipeline. CEO and CSO Martin Brenner will present updates on the company's next-generation antibody medicines, including IBIO-600, their long-acting Myostatin treatment, and new preclinical data on Activin E.

The presentation will also reveal a third target in their AstralBio Collaboration. The company aims to develop targeted, longer-lasting therapies with improved tolerability and sustainable efficacy. Investors can access the webcast through iBio's website, with a replay available for approximately 60 days.

iBio has initiated a non-human primate (NHP) study for IBIO-610, its first-in-class Activin E antibody candidate, following promising preclinical results. The study will evaluate pharmacokinetics and efficacy in obese, elderly NHPs, with initial data expected in early Q4. Preclinical data showed IBIO-610 achieved 8.9% body weight loss alone and demonstrated significant fat reduction capabilities: 26% overall fat reduction and 31% subcutaneous fat reduction. When combined with GLP-1 therapy, these numbers increased to 77% and 74% respectively. Notably, IBIO-610 prevented weight regain after GLP-1 treatment discontinuation in diet-induced obese mice. These findings will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23rd in Chicago.

iBio (NASDAQ: IBIO) has announced promising preclinical results for its first-in-class Activin E antibody in treating obesity. In a 4-week study with obese mice, the antibody achieved a 26% reduction in fat mass while preserving muscle mass. The treatment demonstrated significant reductions in various fat deposits: 31% in subcutaneous fat and 34-37% in visceral fat depots linked to cardiometabolic disease risk.

When combined with a GLP-1 receptor agonist, the Activin E antibody showed remarkable synergy, achieving a 77% reduction in total fat mass and total weight loss of 35.3% - surpassing GLP-1 alone by 7.5%. Unlike current obesity drugs that may reduce muscle mass, iBio's approach focuses on fat-specific weight loss, potentially offering a more effective solution for obesity treatment while maintaining physical function and healthy metabolism.

iBio (IBIO) reported its fiscal Q3 2025 financial results and corporate updates. The company reported a net loss of $4.9 million ($0.49 per share) compared to $2.6 million ($0.71 per share) in Q3 2024. R&D expenses increased to $1.9 million from $0.9 million, while G&A expenses rose to $3.0 million from $2.7 million.

Key developments include: uplisting to Nasdaq, promising non-human primate data for IBIO-600 (anti-myostatin antibody), in-licensing of a first-in-class Activin E antibody from AstralBio, and raising $6.2 million through warrant inducement. Cash position stood at $5.2 million as of March 31, 2025, increasing to $10.5 million by May 1, 2025 post-warrant transaction.

iBio, an AI-driven innovator of precision antibody therapies, has secured $6.2 million through a warrant inducement transaction with institutional investors. The deal involves existing warrant holders agreeing to purchase 5,626,685 shares of common stock at a reduced price of $1.11 per share.

As part of the agreement, investors received new warrants to purchase up to 11,253,370 shares at $0.86 per share, with a five-year expiration period. The transaction is expected to close around April 30, 2025, with Chardan serving as the exclusive financial advisor.

The company plans to use the net proceeds for working capital and general corporate purposes. The new securities are being offered through a private placement and will require registration with the SEC before they can be sold in the United States.

iBio (NASDAQ: IBIO) has announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's Machine-Learning Antibody Engine. The antibody shows promise in inducing fat-selective weight loss and protecting against obesity and cardiometabolic disease.

Preclinical studies demonstrated strong antibody binding, inhibition of Activin E signaling, and fat-specific weight loss in an obese rodent model. The antibody represents the first functional inhibitor of Activin E, a genetically validated therapeutic target important for energy balance and fat distribution regulation.

Under the agreement terms, AstralBio provided iBio a $750,000 credit toward the option fee and will be eligible for development and commercialization milestone payments up to $28 million, plus low to mid-single-digit sublicense fees. Additionally, iBio amended its collaboration with AstralBio to add a fifth target for cardiometabolic disease treatment.

iBio (NASDAQ: IBIO) has announced promising data for its lead asset IBIO-600, a novel long-acting anti-myostatin antibody. In non-human primate studies, IBIO-600 demonstrated a potential human half-life of 57-130 days, suggesting possible dosing schedules of once every 3-6 months.

The exploratory study in obese and elderly non-human primates showed dose-dependent increases in lean mass and reductions in fat mass. At 8 weeks, low-dose subjects (5 mg/kg) showed a 3.1% increase in lean mass, while high-dose subjects (50 mg/kg) demonstrated a 5.1% increase.

Additionally, iBio reported interim data for their first-in-class Activin E antibody. In combination with semaglutide, it enhanced total weight loss by an additional 9% beyond GLP-1 therapy alone, achieving 34% overall weight reduction and 72% body fat reduction. The company remains on track for IBIO-600's regulatory submission in Q1 2026.

iBio (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, announced its approval for listing on the Nasdaq Capital Market. The company will transfer its stock exchange listing from NYSE American to Nasdaq, with trading expected to begin on March 4, 2025, maintaining its "IBIO" symbol. Trading on NYSE American will continue until market close on March 3, 2025.

CEO and Chief Scientific Officer Martin Brenner expressed optimism about joining the Nasdaq community of biotech companies, anticipating improved stock visibility, enhanced trading liquidity, and greater exposure to institutional investors.

iBio (NYSEA:IBIO) has reported its fiscal Q2 2025 financial results and corporate updates. The company recorded revenue of $0.2 million and a net loss of $4.4 million ($0.48 per share) for the quarter ended December 31, 2024. R&D and G&A expenses totaled $4.6 million, showing a 3% increase from the previous year.

Key developments include the discovery of a novel Activin E antibody in collaboration with AstralBio, the in-licensing of IBIO-600 (a long-acting anti-myostatin antibody), and the initiation of a bispecific antibody program targeting myostatin/activin A. The company strengthened its Board with the appointments of David Arkowitz and António Parada, and extended its cash runway through a private placement with Board members and Officers.

As of December 31, 2024, the company's cash position stood at $7.2 million, including $0.2 million in restricted cash.